The Use Of UHPLC In Post-Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Use Of UHPLC In Post-Drug Development
Ultra high performance liquid chromatography (UHPLC) offers increased performance compared with high performance liquid chromatography (HPLC), including shorter analysis times and increased sensitivity. These features offer many advantages in post-drug development, helping to reduce both the amount of solvent and sample required and, therefore, the associated costs.


Pharmaceutical Technology Europe
Volume 23, Issue 1

How have UHPLC systems advanced in recent years?

One of the key benefits of newer UHPLC systems is that they can offer combined HPLC/UHPLC operation without sacrificing performance. Although several combined HPLC/UHPLC systems have been available in the market for some time, their main drawback has been loss of performance when operating outside the specific set of conditions they have been optimised for.1 Another limitation has been the lack of quaternary capabilities. Such capabilities require low pressure mixing and in the past, low pressure mixing demanded larger delay (dwell) volumes for optimum performance, which is detrimental for true UHPLC operation to achieve optimum performance and allow proper solvent mixing.

With newly developed pump technology, however, this is no longer the case. This technology employs unique force sensors to modulate pumping efficiency based on assessed mobile phase compressibility; thereby enabling the delivery of accurate and reproducible gradients with extremely low delay volumes. The force sensors employed in these pumps measure the actual force that is needed to move each piston and can be used to determine compressibility of the displaced solvent in real-time. As such, variations in compressibility caused by changes in mobile phase composition and temperature, etc., can be accounted for and compensated during each individual piston stroke. The end result is volumetric, virtually pulsation free flow from the pump over its complete dynamic working range. The high stability of flow and pressure also eliminates the need for a pulse dampening device, which increases ease of use. Overall, the technology has helped increase the accuracy and reliability in pump performance under all operating conditions.

Some newly developed systems also offer quaternary mixing capabilities, which are extremely useful when developing chromatographic methods and when more than two solvents are needed to achieve adequate chromatographic resolution, such as when working with complex samples.

Sergio Guazzotti is Senior Global Product Marketing Manager, Liquid Chromatography at Thermo Fisher Scientific

Reference

1. Thermo Fisher, Application Note 405: Analysis of Simvastatin Tablets by High Speed LC (2007). http://www.thermo.com/appnotes


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here